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Abstract
Adequate understanding of radiopharmaceutical distribution in the body of the 
patient has both spatial and temporal characteristics and they are the key factor to 
consider when planning successful radio pharmaceutical therapy, because they are an 
integral part of the radiation dosimetry calculations of any proposed personalized treat-
ment. In this chapter we will focus on radioiodine therapy for thyroid cancer patients 
since it is a widely known practice in clinical oncology. Factors affecting the radioiodine 
organs’ distribution will be examined in sufficient details using the available published 
research in the scientific literature. The literature will be reviewed extensively and sum-
marized in this chapter. Another aim is to provide the medical practitioners with a quick 
reference guide to this clinically important area of expertise; often mastered by medical 
physicists with background in radiation physics, mathematics and medical imaging 
analysis. This chapter will cover recent advances in the area of radioiodine biodistribu-
tion modeling with applications in preclinical and clinical studies.
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1. Introduction
This chapter will focus on presenting a review of the current situation regarding the 
use of radioiodine labeled agents in clinical and preclinical nuclear medicine imaging 
and radionuclide therapy. We will show the actual clinical applications and summarize 
the preclinical and clinical research efforts undergoing today in this dynamic field of 
medicine. These agents were found to be interesting since they can be applied to both 
imaging the disease and for therapy, by delivering a will localized radiation dose to a 
target tissues or tumor volume within the human anatomy. This delivery is carried out 
by the so called carrier systems such as, monoclonal antibodies or fragments of those 
and also by nanoparticles both inorganic and organic and microspheres. These carriers 
will carry the radioactivity of the radionuclide to the targeted biological site. There are 
two types of targeting the first is direct targeting, when the pharmaceutical accumula-
tion in a tissue or site is done through inherent pathophysiological characteristics; or 
indirect which occurs if the used carries possess higher affinity to bind to a particular 
cell type or tissue. The good example of such radiopharmaceutical is tositumomab 
Radiopharmaceuticals
2
(131I-labeled anti-CD20 antibody), which received Food and Drug Administration 
(FDA) approval for the treatment of Non-Hodgkin’s lymphoma in 2003.
2. Biodistribution modeling
Physical and temporal variability of the iodine −131 activity distributions in 
tissue constitute what is commonly called bio distribution models. The models are 
based on what is known in mathematics as compartmental modeling. For the sake 
of radiation dose calculations scientist may use different models to estimate the 
activity present in the patient body and the fraction of the radioactivity released 
from his or her body using simple two compartment model. More rigorous models 
also exist, having more than five compartments.
Biodistribution experiments are also published and new ones are still being pub-
lished it is a dynamic field of research. The same apply for different radiopharmaceuti-
cals. Organs Residence time is one important factors being measured while developing 
a bio distribution experiments leading to the proposal of a new bio distribution model.
Factors altering such models are very important to be aware of, because the alter-
ation in the bio distribution will directly impact the radiation dose calculations and 
therefore the safety of the patients undergoing radioiodine therapy. To the best of 
our knowledge there are no general agreement on the methods or standards applied 
when reporting bio distribution studies. Therefore we will attempt to summarize 
the ones in the literature.
2.1 Biokinetic data
Biokinetic data are variables that describe the bio distribution space time functions.
Among the most common of these variables are: the uptake fraction by the organ 
example the thyroid, the excreted fraction as (urine or feces), the biological half-
life or time in a specific organ or body tissues like blood, thyroid, and intestine for 
example. The fractions are mostly given as % and the time are often given in days 
most of the times in the case of radioactive iodine. Biokinetic data for radioactive 
iodine are reported in ICRP-30 [1].
2.2 Radionuclide delivery system
Radionuclide delivery systems are now as antibodies, nanoparticles both inor-
ganic and organic and finally as Microspheres.
In this reference good information is given on targeted radionuclide therapy 
for the thyroid cancer treatment. Parallelism is shown between preclinical animal 
models in rats and mice versus humans [2].
Translation of the experimental findings and research results is an issue that 
warrants the attention of the researcher; in this case the range of radiation in tissues 
and the organ sizes needs to be considered. Also the difference among the metabo-
lism and metabolism rate models used directly affects the biodistribution in the 
animal or the human under study.
2.3 Compartmental biological modeling
Compartmental models are used for internal radioisotope ingestions or injec-
tions dosimetry since the seventies. We are referring to the ICRP publication 30 
published in 1979. In that documents several compartmental models are proposed, 
we focus on the model proposed for iodine metabolism in humans.
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In order to apply the model a set of differential equations has to be solved simulta-
neously to obtain the biodistribution of iodine in human body. The equations can be 
solved numerically using algorithm included in software like Mathematica or Matlab.
Biokinetic models parameters are taken for healthy individuals. In order to apply 
the models to cancer patients for example, the metabolic data has to be customized 
to represent their actual metabolism status. Currently, scientists are recommend-
ing the use of personalized radiopharmaceutical therapy where each therapeutic 
procedures is planned based on the individual patient data and not using the generic 
data from reports like ICRP and others.
The following 4 differential equations are for the model in Figure 1:
 ( )pdq / dt q= - +l l1 12 1  (1)
Figure 1. 
Five compartments human body biokinetic model of iodine as per ICRP-30 report.
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 ( )pdq / dt q q q= - + + +l l l l l2 12 1 25 23 2 42 4  (2)
 ( )pdq / dt q q= - +l l l3 23 2 34 3  (3)
 ( )pdq / dt q q= - + +l l l l4 34 3 42 45 4  (4)
This five compartment model is the one proposed by the −30 to represent the 
biokinetic model of iodine in healthy individuals.
After solving the system of simultaneous four differential equations above the 
solution yield the following.
 ( ) ( ) ( ) ( )/ /T thy d,T Body Fluid d,i thy %,i excretion %.= = = =1 2 1 2 23 2580 0.25 30 70  
These results are for the healthy individuals, solving the same system for thyroid 
cancer patients yields the following [3, 4]:
 ( ) ( ) ( ) ( )/ /T thy d,T Body Fluid d,i thy %,i excretion %.= = = =1 2 1 2 23 250.66 0.52 12 88  
We can see that there is a significant difference in the values obtained. Where 
the importance of personalized dose estimates, the analysis of the results dictates 
the importance to take into account the pathology of the patients and his thyroid 
disease status and diagnosis before interpreting the results of any biokinetic experi-
ment or data analysis.
2.4 Biodistribution studies and biokinetic models
The radiopharmaceutical kinetic data often known as Biodistribution is a 
function of space and time. Imaging the whole body or specific region using planar 
scintillation Gamma camera can be used to obtain the necessary data for the study. 
The accuracy of this method is better when the radiopharmaceutical is localized in 
a specific area of the body or organ and this region do not overlap with other uptake 
area in the planar projection.
A region of interest (ROI) is determined in order to estimate the absolute 
amount of radioactivity in the organ. Modern Gamma cameras provide capability 
to delineate ROI of nay shape and to perform statistical analysis on the pixels inside 
the ROI to obtain the number of counts per pixel inside the ROI and the count rate.
Sequential imaging as a function of time postadministration of the radiophar-
maceutical provides the time dependence of activity (time-activity curve) [5]. In 
this reference a full description of the imaging based method using planar gamma 
camera, SPECT and PET are described in great details.
Clinical and preclinical imaging protocols are published by different groups of 
scientists worldwide. Imaging is the key part of the bio distribution data acquisition 
experiment and constitutes the primary data for the model that will be proposed 
based on the results obtained during the experiment.
Imaging acquisition at different times after oral administration of a known 
activity of I-131 1100 MBq is the most common used with human subjects. Using 
a clinical gamma camera scanned data form the organs of interest, example the 
5
Recent Advances in Biodistribution, Preclinical and Clinical Applications of Radiolabelled Iodine
DOI: http://dx.doi.org/10.5772/intechopen.99113
stomach using an region of interest (ROI) is converted to counts per pixel per sec. 
Will be acquired and data will be extracted for further analysis.
2.5 Image- based, patient- specific dosimetry
Such technique will allow the distribution of the agent in tumors and normal 
organs to be quantified [6]. Dosimetry as implemented in RPT may be thought 
of as the ability to perform the equivalent of a pharmacodynamic study in treated 
patients in real time [7]. When patient dosimetry is performed it allow prediction 
of treatment success based on reported results in the literature, it is then possible to 
calculate both normal tissue and tumor doses.
Organ uptake, Reminder of body uptake, Assumed waste. Derivation of the 
biological half –life values in different organs: they are theoretical estimations of 
the time-dependent quantity of I-131 in various compartments.
In Ref. [7] the authors have found that estimated biological half-life’s obtained 
via the biokinetic model of radioiodine for thyroid cancer patients was found 
to strongly deviate from those recommended by Eckerman’s suggestion for 
healthy male.
2.6 Organs residence times
By definition lambda is given by:
 ( ) /Ln / T=l 1 22  (5)
Where T1/2 is the half-life. it could be the biological (Tb), physical (Tp) or effec-
tive (Teff) half-life depending on the application.
Knowing that:
 eff b p/ T / T / T= +1 1 1  (6)
The biological half-life of radiopharmaceuticals is organ dependents. We will 
observe dissimilar values for different organs.
Time integrated activity coefficients (TIAC) are known also as organs resi-
dence times. They are proportional to the radiation absorbed dose by the organ or 
body tissue.
The radiopharmaceutical effective half-life is different for each organ in the 
body. And they are dependent of the biodistribution or the individual organ uptake 
fraction of the total injected activity. The same applies to the tumor tissues targeted 
by the radiopharmaceutical therapy; in our case here it is the remaining of the post 
ablation thyroid tissues treated using I-131.
3. Radioactive iodine treatment for thyroid cancer patients
In many medical applications involving the administration of iodine-131 (131I) in 
the form of iodide (I−), most of the dose is delivered to the thyroid gland [3].
To reliably estimate the thyroid absorbed dose, the following data are required:
the thyroid gland size (i.e. mass), the fractional uptake of 131I by the thyroid, the 
spatial distribution of 131I within the thyroid, and the length of time 131I is retained 
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in the thyroid before it is released back to blood, distributed in other organs and 
tissues, and excreted from the body [4, 8–10].
Estimation of absorbed dose to non-thyroid tissues likewise requires knowledge 
of the time course of activity in each organ. Such data are rarely available, however, 
and therefore dose calculations are generally based on reference models. The MIRD 
and ICRP have published metabolic models and have calculated absorbed doses per 
unit intake for many nuclides and radioactive pharmaceuticals. Given the activity 
taken into the body, one can use such models and make reasonable calculations for 
average organ doses. When normal retention and excretion pathways are altered, 
the baseline models need to be modified, and the resulting organ dose estimates are 
subject to larger errors.
Even if the uptake of iodine is very specific to thyroid tissue, side effects from 
off-target accumulation are common. Frequent short-term side effects after 131I 
therapy of patients with differentiated thyroid cancer are gastrointestinal symp-
toms, pain or swelling in the neck or salivary glands, while frequent late effects are 
functional problems with salivary glands [11–15].
The hypothalamus-pituitary-thyroid (HPT) axis is an example of an endocrine 
feedback loop that is known to have a circadian rhythm [16].
Patients with chronic renal failure exhibited significant salivary gland, oral, 
nasal, and gastric activity 1 week after radioiodine administration [17].
3.1 Sodium/iodide symporter (NIS)
Active iodide (I−) transport in both the thyroid and some extra-thyroidal tissues 
is mediated by the Na+/I− symporter (NIS).
The cDNA encoding NIS was isolated in 1996, marking a major breakthrough in 
thyroid research that led to the subsequent characterization of NIS at the molecular 
level. Functional NIS is found in several extra-thyroidal tissues, such as the salivary 
glands, stomach, and lactating breast, as well as in primary and metastatic breast 
cancers. The latter findings have raised the possibility that NIS-mediated 131I− treat-
ment may be effective in breast cancer. One of the most remarkable properties of 
NIS is that it transports different substrates with different stoichiometries. TSH is 
the primary regulator of NIS in the thyroid at both the transcriptional and post-
transcriptional levels. At the molecular level, excess I− may have a deleterious effect 
on the thyroid by modifying NIS mRNA stability and increasing the production of 
reactive oxygen species. Thyroidal NIS function is also regulated by direct cross talk 
between NIS and a K+ channel [18].
3.2 Future perspective and applications
In the last two decades, NIS has become an important player in the use and 
optimization of gene therapy owing to its capacity as a reporter and as a therapeutic 
gene. NIS could be introduced into virtually any cell or tissue for imaging and/or 
therapeutic purposes. NIS is becoming the counterpart for human studies of green 
fluorescent protein and luciferase, which have been used extensively in cells and 
other organisms.
NIS expression and activity correlate with cell viability because only living cells 
can accumulate I−. NIS also offers higher detection sensitivity, because it actively 
transports its substrates rather than simply binding a substrate stoichiometrically. 
Moreover, NIS can translocate a variety of substrates, which can be detected using 
different systems, such as gamma cameras, PET, and SPECT (single-photon emis-
sion computed tomography) combined with computed tomography (CT) [18].
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4. Newly introduced I-131 labeled radiopharmaceutical therapy agents
Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted 
approach to treating many types of cancer. In RPT, radiation is systemically or 
locally delivered using pharmaceuticals that either bind preferentially to cancer 
cells or accumulate by physiological mechanisms. Almost all radionuclides used in 
RPT emit photons that can be imaged, enabling non-invasive visualization of the 
biodistribution of the therapeutic agent. Compared with almost all other systemic 
cancer treatment options, RPT has shown efficacy with minimal toxicity. With 
the recent FDA approval of several RPT agents, the remarkable potential of this 
treatment is now being recognized [6]. We will mention a few emerging clini-
cal development of radioiodine labeled RPT agents newly available or still under 
development at the present time. RPT development is a multidisciplinary endeavor, 
requiring expertise in radiochemistry, radiobiology, oncology, pharmacology, medi-
cal physics and radionuclide imaging and dosimetry.
Theranostic is the general concept of using a radionuclide- labeled agent that 
may be imaged to guide radiopharmaceutical therapy; a radionuclide that may be 
used for both imaging and therapy, and it is the new trend in RPT.
I-131 meta- iodobenzylguanidine (mIBG): for Adrenergic receptor tumors; the 
active uptake mechanism via the adrenaline transporter and storage in presynaptic 
neurosecretory granules. FDA approved but clinical trials are ongoing. This radio-
pharmaceutical can be used to treat patients with neuroblastomas [19].
mIBG radiolabelled with high- specific- activity iodine-131 was recently 
approved by the FDA for the treatment of adult and pediatric patients aged 12 years 
or older with unresectable metastatic phaeochromocytoma or paraganglioma.
I-131- labeled CLR131 for Pediatric cancer, head and neck cancer, multiple 
myeloma, leukemia, lymphoma. The radio-labeled phospholipid ether analogue 
targeting cancer cell- specific lipid raft microdomains. It is still undergoing the 
phase of clinical trials and testing.
I-131- labeled CLR1404 for unresponsive solid tumor, multiple myeloma. The 
radio-labeled phospholipid ether analogue targeting cancer cell-specific lipid raft 
microdomains. It is still undergoing the phase of clinical trials and testing.
4.1 Antibody based radionuclide therapy
Radiolabeled sdAbs prove to be promising vehicles for molecular imaging and 
targeted radionuclide therapy of metastatic lesions in the brain. Administration of 
[I-131]-2Rs15d and [Ac-225]-2Rs15d alone and in combination with trastuzumab 
showed a significant increase in median survival in 2 tumor models that remained 
largely unresponsive to trastuzumab treatment alone [20]. Puttemans et al. [21] 
have described the use of the anti-HER2 sdAb 2Rs15d, coupled to 111In or 131I for 
detection via PECT/CT, and coupled to 131I or 225Ac for targeted radionuclide 
therapy (TRNT) of HER2pos brain lesions and compare its therapeutic efficacy 
and systemic toxicity to that of trastuzumab, a clinically-approved anti-HER2 
treatment. They have demonstrated that radiolabeled sdAbs are ideal vehicles for 
targeted radionuclide therapy and molecular imaging, not only for systemic disease, 
but also for metastatic lesions in the brain. Moreover, histopathological analysis 
after therapy revealed no significant early toxicity. Dosimetry based on ex vivo 
biodistribution data confirmed most activity is retained within the kidneys until 
48 h after administration, however after extrapolation to therapeutic activities the 
cumulative absorbed dose (25 Gy) remains close to the considered toxicity thresh-
old of 23 Gy to kidneys [21].
Radiopharmaceuticals
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The amount of 131I- tositumomab prescribed to patients was determined by 
assessing the whole- body clearance rate, so that the amount administered was 
adjusted to deliver the same whole- body absorbed dose in all treated patients 
[21], making it the first RPT agent whose package insert specified an absorbed 
dose- based treatment planning procedure. Such an approach was, in part, neces-
sitated because the radioiodine in iodine-131- labeled antibodies is cleaved (due 
to dehalogenation) from the antibody if the radiolabelled antibody construct is 
internalized.
4.2 Iodine-131 labeled Metuximab
Radioimmunotherpy using antibodies injection is another application of I-131 
in oncology. Administered to patients suffering from hepatocellular carcinoma 
(HCC), the product will target the hepatic cancer cells while sparing other adjacent 
tissues. The whole body biodistribution is required in order to perform radiation 
dosimetry, evaluate the risk from the treatment and to ensure patient safety.
4.3 I-131 - labeled a CD45
I-131 - labeled a CD45 for Bone marrow transplant preparation.
The I-131 based antibody targeting CD45+ cells for bone marrow ablation before 
transplantation. It is still undergoing the phase of testing and planned clinical trials. 
Early studies showed the potential to image the radioiodinated antibodies using 
SPECT [22, 23].
The radiolabelled antibodies were used for total body irradiation in preparation 
for bone marrow transplantation (BMT). report results of a study on patients with 
acute myelogenous leukemia in a phase I clinical trial where results showed that it is 
possible while appending I-131 to M195 antibody to deliver beta emitter particles to 
the targeted cells in the bone marrow, it was also possible to image the disease in the 
bone marrow.
The tumor-homing property of mesenchyme stem cells (MSCs) allows targeted 
delivery of therapeutic genes into the tumor microenvironment. The application of 
sodium iodide symporter.
(NIS) as a theranostic gene allows noninvasive imaging of MSC biodistribu-
tion and transgene expression before therapeutic radioiodine application. Linking 
therapeutic transgene expression to induction of the chemokine CCL5/RANTES 
allows a more focused expression within primary tumors, as the adoptively trans-
ferred MSC develop carcinoma-associated fibroblast-like characteristics. Although 
RANTES/CCL5-NIS targeting has shown efficacy in the treatment of primary 
tumors, it was not clear if it would also be effective in controlling the growth of 
metastatic disease. To expand the potential range of tumor targets, we investigated 
the biodistribution and tumor recruitment of MSCs transfected with NIS under 
control of the RANTES/CCL5 promoter (RANTES-NIS-MSC) in a colon cancer 
liver metastasis mouse model established by intrasplenic injection of the human 
colon cancer cell line LS174t. Results show robust MSC recruitment with RANTES/
CCL5-promoter activation within the stroma of liver metastases as evidenced 
by tumor-selective iodide accumulation, immunohistochemistry, and real-time 
polymerase chain reaction. Therapeutic application of 131I in RANTES-NIS-MSC–
treated mice resulted in a significant delay in tumor growth and improved overall 
survival. Conclusion: This novel gene therapy approach opens the prospect of 
NIS-mediated radionuclide therapy of metastatic cancer after MSC-mediated gene 
delivery [24].
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4.4 Newly introduced radioiodine labeled nanoparticles and microspheres
in the area of preclinical development regarding tumor targeted therapy using 
radioiodine labeled molecules an active research work is undergoing using Nano 
and microsphere technologies. The good example of such radiopharmaceutical is 
tositumomab (131I-labeled anti-CD20 antibody), which received Food and Drug 
Administration (FDA) approval for the treatment of Non-Hodgkin’s lymphoma 
in 2003.
Initial clinical trials of 131I- labeled iodized oil (131I- labeled Lipiodol) were 
completed in the late 1980s/early 1990s (285–288), and clinical investigations of 
this treatment modality continued until 2013 (NCT00116454, NCT00870558 and 
NCT00027768).
Administration of 131I- labeled Lipiodol in the adjuvant setting, after resec-
tion or radiofrequency ablation for hepatocellular carcinoma, yielded a 6- month 
increase in recurrence free survival and a 24- month increase in median overall 
survival [25].
RPT has proven to be an effective cancer treatment when other standard thera-
peutic approaches have failed. However, despite more than 40 years of clinical 
investigation, RPT has not become a part of the cancer treatment armamentarium 
in the same way as other therapies. ‘Targeted’ cancer therapies are associated 
with clinical trial failure rates of 97% (ref. 1), partly because the agents targeted a 
pathway that was not involved in promoting the cancer phenotype2. By contrast, 
RPT has been unsuccessful owing to a failure to adopt and rigorously evaluate this 
treatment modality, which may be explained in part by the multidisciplinary nature 
of the treatment.
Additional challenges facing the development and application of RPT include 
public perception and fear of radioactivity as well as the perceived complexity of 
the treatment.
The need for a new specialty or subspecialty to provide the multidisciplinary 
training needed to safely and effectively administer RPT agents to patients and 
subsequently manage them. Such a specialty or subspecialty would require train-
ing in nuclear medicine, radiation oncology and also general oncology as delivery 
of radiation is involved, the participation of medical physicists familiar with both 
imaging and radionuclide dosimetry is important.
The article by Jongho Jeon [25], reviews recent progress in cancer therapy using 
radiolabeled nanomaterials including inorganic, polymeric, and carbon-based 
materials and liposomes. The article first provides an overview of radiolabeling 
methods for preparing anticancer agents that have been investigated recently in 
preclinical studies. Next, they discuss the therapeutic applications and effective-
ness of beta or alpha emitter-incorporated nanomaterials in animal models and the 
emerging possibilities of these nanomaterials in cancer therapy [26].
In contrast to biologics or chemotherapeutics, both radiation delivery and the 
biological response to radiation may be mathematically modeled and used to under-
stand the parameters of a treatment that are most important in influencing efficacy 
and toxicity. The capability to use multiple agents in one carrier is very unique about 
nanomaterials [27].
5. Conclusion
Unlike chemotherapy and external beam radiation therapy RPT has not yet been 
established as a treatment modality in oncology. Mainly because lots of suggested 
Radiopharmaceuticals
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RPT agents are still undergoing clinical trials and some are still in the preclinical 
stage. The known fact is that, the tumor response to RPT can be mathematically 
modeled and also the radiation dosimetry is well established [24, 25]. There are 
research projects underway that focus on the use of combination therapy using 
targeted RPT along with chemotherapy for example in the treatment of resistant 
tumors that cannot be treated uniquely by traditional therapy like chemotherapy, 
this area of research is also quit active at the present time [28].
One challenge is the validation studies and the regulatory approval of clini-
cal software packages that need to be established prior to routine clinical use is 
still underway. Certainly this area of research and development is very dynamic 
and requires multidisciplinary team work including oncology, nuclear medicine, 
imaging sciences and medical physics; and clinically also it will probably require 
some kind of new medical subspecialty. The medical physicist should be trained in 
both imaging based and radionuclide dosimetry methods. As medical physicists we 
see this as an opportunity for future medical physicist starting his or her career to 
specialize in this new evolving area of clinical medical physics.
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